KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short-Term Debt repayments (2023)

Supernus Pharmaceuticals (SUPN) has disclosed Short-Term Debt repayments for 1 consecutive years, with $78.4 million as the latest value for Q2 2023.

  • Quarterly Short-Term Debt repayments changed N/A to $78.4 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $78.4 million through Mar 2024, up 435.38% year-over-year, with the annual reading at $93.0 million for FY2023, N/A changed from the prior year.
  • Short-Term Debt repayments for Q2 2023 was $78.4 million at Supernus Pharmaceuticals, up from $14.6 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $78.4 million in Q2 2023, with the low at $14.6 million in Q1 2023.